Evaluation of the efficacy of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B combined with nonalcoholic fatty liver disease by high-sensitivity detection of HBV DNA levels
10.3760/cma.j.cn501113-20220124-00043
- VernacularTitle:高灵敏检测HBV DNA水平评价富马酸替诺福韦酯治疗慢性乙型肝炎合并非酒精性脂肪性肝病的疗效
- Author:
Chenge LIANG
1
;
Xi WANG
;
Shuhong LIU
;
Xiaofeng SHI
Author Information
1. 重庆医科大学病毒性肝炎研究所 重庆医科大学附属第二医院感染科，重庆 400010
- Keywords:
Chronic hepatitis B;
Tenofovir disoproxil fumarate;
Non-alcoholic fatty liver disease
- From:
Chinese Journal of Hepatology
2023;31(2):113-117
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of tenofovir disoproxil fumarate (TDF) antiviral therapy in patients with chronic hepatitis B (CHB) combined with nonalcoholic fatty liver disease (NAFLD), so as to provide evidence-based evidence in these special populations.Methods:Data from 91 CHB cases who received TDF 300 mg/d antiviral therapy for 96 weeks were analyzed retrospectively. Among them, 43 cases with NAFLD were included in the study group, and 48 cases without NAFLD were included in the control group. The virological and biochemical responses of the two groups of patients at 12, 24, 48, and 96 weeks were compared. Among them, 69 patients underwent highly sensitive detection of HBV DNA. The t-test and χ2 test were performed on the data. Results:ALT normalization rate was lower in the study group (42%, 51%) at 12 and 24 weeks of treatment than that in the control group (69%, 79%), and the difference was statistically significant ( P < 0.05). However, there was no statistically significant difference between the two groups at 48 and 96 weeks. HBV DNA concentration below the lower limit of detection (200 IU/ml) was lower in the study group at 12 weeks of treatment than in the control group (35% vs. 56%), and the difference was statistically significant ( P < 0.05). However, there was no statistically significant difference between the two groups at 24, 48, and 96 weeks. Furthermore, HBV DNA concentration below the lower limit was significantly lower in the study group than that in the control group at 12, 24, 48, and 96 weeks of treatment when the lower limit of HBV DNA detection was set at 20IU/ml, and the difference was statistically significant ( P < 0.05). The HBeAg serological negative conversion rate was gradually higher in the study group at 48 and 96 weeks of treatment than in the control group, and the difference was not statistically significant. Conclusion:TDF antiviral treatment can affect the virological and biochemical responses of NAFLD in chronic hepatitis B.
